newsfilter
← Latest News
PR Newswire·

IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

IDYA
  • IDEAYA Biosciences, Inc. announced an underwritten public offering to sell up to $300.0 million of common stock & pre-funded warrants.
  • The company intends to grant underwriters a 30-day option to purchase an additional $45.0 million of shares.
  • J.P. Morgan, Jefferies, TD Cowen, UBS Investment Bank, & Cantor are serving as joint book-running managers.
  • The offering is being conducted pursuant to an automatically effective shelf registration statement on Form S-3 filed with the SEC.
  • The transaction is subject to market conditions, with no assurance provided regarding completion, size, or terms.
  • IDEAYA is a precision medicine oncology company focused on developing targeted therapies for solid tumors via synthetic lethality & antibody-drug conjugates.
  • Forward-looking statements in the release are subject to risks including market conditions, regulatory outcomes, & drug development uncertainties.